Enamine Ltd., a leading chemical research organization and producer of the worldâs largest collections of novel building blocks and screening compound libraries, and BioSolveIT GmbH, announced the launch of the âREAL Space Navigatorâ.
Symcel â the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, calScreener â is expanding to bring its patented technology to the clinical antimicrobial susceptibility testing (AST) markets.
During the Society of Toxicology Meeting from 11-15 March 2018, Lonza will present two posters highlighting its latest research into developing more physiologically relevant in vitro cell-culture models for ADME-Tox testing.
New liquid handling platform reduces assay development time and improves assay robustness in high throughput screening. Global commercial launch at SLAS 2018 from 3rd to 7th February 2018, in San Diego, CA, Booth #1219.
Acquisition increases Conceptâs global reach and supports growth strategy. Synergies with Spectrisâ molecular testing and analysis expertise will provide customers with access to a broader range of services.
Avacta Group plc and OncoSec Medical Incorporated, are pleased to announce they have entered into a research collaboration to combine Avactaâs Affimer protein platform with OncoSecâs gene delivery technology ImmunoPulse.
LifeArc, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, have announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.
IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTASâ proprietary Mammalian Display Technology.
SYGNIS AG, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Innova Biosciences brand, to support scalability and bulk production of antibodies.
Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully.
Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Helen McKeever as Programme Manager for the Group, and David Halverson as US Head of Sales.
Now in its 18th year, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and a must read journal within the discovery and development arena.